New drug trial aims to help millions with liver damage from hepatitis b
NCT ID NCT07343778
Summary
This study is testing the safety of a higher dose of hydronidone capsules in people with liver scarring (fibrosis) and cirrhosis caused by chronic hepatitis B. 300 adult participants will take the capsules for 28 days and be monitored for side effects. The goal is to gather safety information to potentially help control liver disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B WITH HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth People's Hospital of Zhengzhou City
Zhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.